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ABSTRACT: The pH-dependent intramolecular chelation of a tethered sulfonamide ligand in ruthenium(II)-arene complexes is 
demonstrated; a process shown to modulate metal-centered reactivity toward the model ligand guanosine 5'-monophosphate within 
the physiologically relevant pH region.
Ruthenium(II)-based organometallic compounds continue to 
be intensively investigated as prospective anticancer metal-
lodrugs,1 prompted by early work that identified promising anti-
angiogenic and antimetastatic activity within the [Ru(η6-
arene)Cl2(PTA)] (RAPTA) series
2 of compounds and antitumor 
activity within the [Ru(η6-arene)(en)Cl]+ series3 of compounds.  
Metallation of protein and/or DNA targets, usually through dis-
placement of a coordinated H2O molecule by a donor atom pre-
sent within the biomacromolecule, is believed to form the basis 
of the anticancer activity for many of these organometallic spe-
cies.4 A limitation of such compounds is that their reaction with 
DNA/proteins can, in principle, occur in both healthy and can-
cerous tissue and would lead to indiscriminate reactivity in vivo, 
likely accompanied by serious side-effects. 
The development of ruthenium(II) compounds whose ligands 
afford intrinsic control over metal-centered reactivity in a man-
ner dependent on the local chemical environment would lead to 
more selective metallodrugs.  For example, the known differ-
ences between the extracellular pH of tumour tissue (6.5-6.9) 
and that of healthy extracellular tissue (7.2-7.4)5 may be ex-
ploited by the development of ruthenium(II)-based organome-
tallic compounds exhibiting pH-dependent reactivity profiles. 
Several reports have described preliminary investigations to-
ward developing metallodrugs with such pH-dependent behav-
iour.  In 2001 the prototypical RAPTA compound [Ru(η6-p-cy-
mene)Cl2(PTA)] was shown to exhibit pH-dependent DNA 
binding, with increased binding observed below pH 7.0.6  How-
ever, subsequent studies have shown that DNA is unlikely to be 
a major cellular target of RAPTA compounds.7  A subsequent 
approach to render the reactivity of RAPTA compounds pH-
dependent utilized fluoroarene ligands to yield a small series of 
[Ru(η6-fluoroarene)Cl2(PTA)] (fluoroarene = 1,4-C6H4CH3F, 
C6H5F, C6H5CF3) structures.
8  The calculated pKa values of the 
aqua ligand in [Ru(η6-fluoroarene)Cl(H2O)(PTA)]+ were de-
pendent on the fluoroarene utilized (8.9, 8.3 and 5.5 when 1,4-
C6H4CH3F, C6H5F, C6H5CF3 respectively) and the rate of aqua-
tion of [Ru(η6-C6H5CF3)Cl2(PTA)] was faster at pH 4.7 com-
pared to pH 5.7.  However, NMR analysis of the complexes re-
vealed varying degrees of fluoroarene loss on incubation of the 
compounds in aqueous solutions which clearly limits future ex-
ploration of their pH-dependent reactivity.  Building on an ear-
lier precedent,9 a recent study has described the activation of or-
ganometallic ruthenium(II) compounds via ring-opening of an 
η6:κ1-arene/N chelate under acidic conditions.10  The ‘activated’ 
ring-opened form of the complexes were able to bind to guano-
sine 5'-monophosphate (5'-GMP); however, the pKa value of 
the ligand (ca. 2.5) renders the complexes inactive and unable 
to bind to 5'-GMP under physiologically relevant pH condi-
tions.  Similar ruthenium(II)-complexes bearing η5-cyclopenta-
dienyl or η6-arene ligands with pendant thiophene,11 amine12 or 
hydroxy12 groups able to form an intramolecular chelate via het-
eroatom ligation to ruthenium have also been reported.  How-
ever, the described systems are unsuited to regulate metal-cen-
tered reactivity under physiological conditions due to the forc-
ing conditions required to either form or ring-open the chelate.  
It is clear that although progress has been made toward achiev-
ing the goal of pH-dependent modulation of ruthenium-cen-
tered activity, methods are lacking in order to extend this to the 
physiologically relevant pH-region.  A series of reports have 
described the application of reversible intramolecular sulfona-
mide ligation to modulate, in a pH-dependent manner, the co-
ordination environment of the central ion in lanthanide com-
plexes.13  With these studies in mind we postulated that the in-
troduction of a pendant sulfonamide group to the arene ligand 
of an organometallic ruthenium(II) complex would permit the 
reversible pH-dependent formation of an intramolecular chelate 
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via displacement of a labile aqua ligand (Scheme 1).  We envis-
aged that this process could be employed to regulate metal-cen-
tered coordination to target ligands and could be tuned, through 
modulation of the basicity of the sulfonamide nitrogen via var-
iation of the R substituent, to afford control across the physio-
logically relevant pH range.  Here we report the synthesis of 
two ruthenium(II) organometallic compounds bearing a pen-
dant sulfonamide group and studies into their pH-dependent re-
activity in aqueous solution. 
Two ruthenium(II) arene complexes bearing a pendant sul-
phonamide moiety, [Ru(η6-C6H5CH2CH2NHR)(C2O4)(H2O)] 
(R = Ms, Tf, 1 and 2 respectively), have been prepared in good 
yield via the reaction of the respective ruthenium(II) dimers, 
[RuCl2(η6-C6H5CH2CH2NHR)]2 (R = Ms, Tf14), with silver ox-
alate.  An analogous complex, [Ru(η6-
C6H5CH2CH2NHCOCH3)(C2O4)(H2O)] (3), bearing a pendant 
N-acetyl group was also synthesised from its respective ruthe-
nium(II) dimer, [RuCl2(η6-C6H5CH2CH2NHCOCH3)]2.15  Com-
plexes 1-3 are readily soluble in water and possess good stabil-
ity at 310 K in the presence of bovine serum albumin (BSA) and 
NaCl (Figs. S19-21), with the Ru-arene bond remaining intact 
under these conditions.  All complexes were characterized by 
1H and 13C (and 19F in the case of 2) NMR spectroscopy, high-
resolution mass spectrometry and elemental analysis.  Single 
crystals of 1 and 3 were grown by vapour diffusion and their 
molecular structures confirmed by single crystal X-ray crystal-
lography (Fig. 1).  Crystallographic data for [RuCl2(η6-
C6H5CH2CH2NHTf)]2 and an analogue of 2b is also reported 
(Figs S2-4, Table S1).     
NMR studies were performed on 1-3 at 295 K to gain a pre-
liminary insight into their solution behavior.  1H NMR spectra 
of 1 in pure D2O exhibited a single set of signals in the arene 
region, attributed to the aqua form of the complex.  In contrast, 
spectra of 2 exhibited two sets of signals in the arene region, 
corresponding to the aqua and chelate (2b) forms of the com-
plex.  The appearance of a further set of signals in the arene 
region in D2O solutions of 1 and 2 containing 100 mM NaCl 
were attributed to the formation of the chlorido analogues of 1 
and 2 in each case (Figs. S13-14).   
Examination of 1H NMR spectra (2.46 mM, D2O, 295 K, 0.1 
M NaCl) of 1 and 2 as a function of pH revealed reversible 
changes indicative of pH-dependent intramolecular sulphona-
mide ligation.  For both 1 and 2 the open (aqua and chlorido 
analogues) and chelate (1b, 2b) forms of the complexes were 
distinguished by unique sets of signals, the intensity of each set 
of signals being pH-dependent (Figs. S15-16).  It is worth not-
ing that a single signal is observed for each −CH2− group in 1b 
and 2b; this signal being at the average chemical shift of the 
protons within each group due to the trigonal-planar geometry 
at the ligated N atom (Figure S4) and fast chemical exchange 
processes.  Analysis of the ratio of selected ligand signals (those 
corresponding to the -CH3 group in the case of 1, or the meth-
ylene bridge connected to the arene group for 2) corresponding 
to the open and chelate forms of the complex allowed a plot of 
Scheme 1.  Compounds 1-3 and pH-dependent intramolecu-
lar chelate formation. 
Figure 1.  Molecular structures of 1 (left) and 3 (right).  Atoms 
are drawn as 50 % probability ellipsoids. Unbound water has 
been omitted from 3 for clarity. Colour scheme: Ru (pink); C 
(grey); H (pale grey); N (blue); O (red); S (yellow). 
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Figure 2.  pH dependence of the proportion of the closed form 
versus the open form of 1 (blue squares) and 2 (black circles) 
(2.46 mM complex, D2O, 295 K, 0.1 M NaCl).  pD values are 
determined using pD = pH meter reading + 0.4.16  Solid red 
lines show the fit of the Henderson-Hasselbalch equation to 
the experimental data. 
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% open form (relative to the chelate form present) versus pD to 
be made, revealing a sigmoidal curve in each case (Fig. 2).  It-
erative least-squares fitting of the Henderson-Hasselbalch equa-
tion to the data determined pKa values of 6.65 and 4.05 for 1 
and 2 respectively; these results are in line with decreasing elec-
tron density at the sulfonamide nitrogen as the R substituent is 
varied from -CH3 to -CF3.  Whilst 
1H NMR spectra of 2 indi-
cated a simple conversion of the open form of 2 (the aqua and 
chlorido species) to the chelate form (ligated sulphonamide) 
over the pH range 2.4-6.4, experiments with 1 revealed the on-
set of an additional equilibrium between [Ru(η6-
C6H5CH2CH2NHMs)(C2O4)(H2O)]/[Ru(η6-
C6H5CH2CH2NHMs)(C2O4)(HO)]
− as the reaction was basified.  
The formation of the hydroxido analogue was evidenced at pD 
values >5.9 by the appearance of an additional set of ligand sig-
nals; over the pD range 6.5-7.4 the proportion of this species 
present remained below 5 %.  This observation was corrobo-
rated through analysis of the 1H NMR spectra of the related 
complex 3 in pure D2O over a range of pD values.  For example, 
at pD 3.65 a single set of arene signals was observed, attributed 
to the aqua form of 3.  Upon basification a second set of arene 
signals appeared (Fig. S12), correlating with those attributed to 
[Ru(η6-C6H5CH2CH2NHMs)(C2O4)(HO)]−. 
The observed biological effects exerted in cellulo and in vivo 
by a wide range of ruthenium(II)-based organometallic species 
is often linked to the ability of these compounds to coordinate 
to DNA and/or proteins, with guanine N7 and the histidine im-
idazole nitrogens being frequently identified as the respective 
binding locations.7b, 17  To investigate whether pH-dependent in-
tramolecular sulphonamide ligation within 1 and 2 could regu-
late such coordination events we performed binding studies 
with the model ligands 5'-GMP and L-histidine.  The reaction 
of 1 with 5'-GMP (30 mM, 1:1, D2O, 295 K, 0.1 M NaCl) over 
a range of pD values was monitored by 1H NMR spectroscopy 
(Fig. S17).  Under acidic conditions where intramolecular che-
late formation is negligible ≈ 90 % of 5'-GMP was coordinated 
to the complex as evidenced through appearance of a new signal 
associated with the guanine H8 proton of 5'-GMP.  On basifi-
cation the equilibrium was perturbed, with increasing formation 
of 1b and concomitant release of 5'-GMP (Fig. 3).  The propor-
tion of coordinated 5'-GMP was found to be 83 % and 58 % at 
pD values of 6.50 and 7.50 respectively18 with Ru-5'-GMP ad-
duct formation found to be reversible – acidification/basifica-
tion of the sample resulted in re-equilibration.  The reaction of 
2 with 5'-GMP at pD 6.41 (30 mM, 1:1, D2O, 295 K, 0.1 M 
NaCl), where the intramolecular chelate 2b is the predominant 
form under these conditions, revealed only low levels of Ru-5'-
GMP adduct formation (8%) (Fig. S18).19  These results are in 
line with the hypothesis that intramolecular sulphonamide liga-
tion is able to regulate Ru-5'-GMP adduct formation and that 
the degree of coordination can be rendered pH-dependent. 
Binding studies between L-histidine and 1 and 2 (30 mM, 1:1, 
D2O, 295 K, 0.1 M NaCl) resulted in complete Ru-L-histidine 
adduct formation in the pD range 6-7.4 via displacement of the 
ligated sulphonamide.  It is clear, in contrast to ruthenium coor-
dination with 5'-GMP, intramolecular sulphonamide ligation is 
unable to regulate L-histidine coordination to the metal and is 
quantitatively displaced by the amino acid.   
An initial evaluation of the cytotoxic activity of complexes 
1-3 was performed against the HT-29 (human colorectal adeno-
carcinoma) cell line.  72 h exposure to compounds 1 and 3 (100 
μM) resulted in no inhibition of cell growth.  In contrast, 2 re-
sulted in 70 % cell death under the same conditions.  Clearly the 
reactivity of 1 towards L-histidine, and its apparent metalation 
of proteins in the cell culture experiments (see Fig. S19 which 
indicates binding between 1 and BSA), does not result in cyto-
toxicity towards this cell line.  The relatively high cytotoxic ac-
tivity of 2 is striking given the structural similarities across the 
series, particularly between 1 and 2.  Further studies are under-
way to probe the origins of this behavior. 
In summary, we have demonstrated that reversible intramo-
lecular sulfonamide ligation in ruthenium(II)-arene systems can 
regulate the core coordination environment around the metal 
ion, in a pH-dependent manner, across the physiologically rele-
vant pH range.  This behaviour bodes well for the future incor-
poration of the pendant sulfonamide moiety into known cyto-
toxic systems to endow them with pH-dependent reactivity to-
ward biomacromolecular targets, the extent of which is con-
trolled by the nature of the local tissue environment.  Further-
more, the differential reactivity of the present systems toward 
5'-GMP and L-histidine within the physiologically relevant pH 
region warrants further exploration.  Such differentiation hints 
at the exciting prospect of metallodrugs able to selectively 
metallate target classes of biomacromolecular targets, or dis-
criminate between different sites within a single biomacromo-
lecular target.  Studies are ongoing in these areas.  
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Figure 3. pH dependence of the proportion of 5'-GMP present 
as Ru-5'-GMP adducts (blue circles) and the chelate-form of 
the complex (red squares) in the reaction between 1 and 5'-
GMP (30 mM, 1:1, D2O, 295 K, 0.1 M NaCl). 
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Detailed synthetic procedures for the synthesis of all novel com-
pounds and copies of their nuclear magnetic resonance spectra, X-
ray diffraction parameters and cell culture protocols.  (PDF)  
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